

Quercetin as a Neuroprotective Agent in Alzheimer's Disease: A Comprehensive Review

Somali Sengupta, Jeenatara Begum*

Guru Nanak Institute of Pharmaceutical Science & Technology, 157/F Nilgunj Road, Panihati, Kolkata – 700114

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by memory loss, cognitive impairment, and behavioral changes, affecting millions worldwide. Current pharmacological treatments provide only symptomatic relief, highlighting the urgent need for novel therapeutic strategies. Quercetin, a naturally occurring flavonoid found in fruits and vegetables, has attracted significant attention for its therapeutic potential in Alzheimer's disease (AD). Its antioxidant, anti-inflammatory, and anti-amyloid properties contribute to its neuroprotective effects, making it a promising compound in AD research. However, the clinical use of quercetin remains limited due to its poor aqueous solubility, low oral bioavailability, and restricted blood-brain barrier (BBB) penetration. Recent advancements in nanotechnology have offered innovative solutions to these challenges. Formulations such as polymeric nanoparticles, solid lipid nanoparticles, and liposomes have been explored to enhance quercetin's pharmacokinetics and targeted brain delivery. For instance, PLGA-based quercetin nanoparticles (PLGA@QT) have shown improved cognitive performance and A β inhibition in AD mouse models. Similarly, quercetin-loaded liposomes administered intranasally demonstrated enhanced brain uptake and improved behavioral outcomes in rats. This review summarizes key findings from in vitro and in vivo studies, highlighting quercetin's mechanisms of action and the significance of nanocarrier systems in enhancing its delivery. Overall, quercetin, when formulated effectively, holds great promise as a disease-modifying agent in the treatment of Alzheimer's disease.

Keywords: Alzheimer's Disease, Natural Polyphenols, Quercetin, Neurodegeneration, Neuroprotection, Nanotechnology, Drug Delivery

Date of Submission: 10-05-2025

Date of acceptance: 21-05-2025

I. INTRODUCTION

Alzheimer's disease (AD), first identified by Dr. Alois Alzheimer in 1906, is a chronic, progressive, and irreversible neurodegenerative disorder that primarily affects elderly individuals and is influenced by various age-related factors [9]. It is the most prevalent neurodegenerative condition, typically manifesting as increasing memory impairment, behavioral disturbances, mood swings, and disruptions in daily activities [1]. Patients with advanced AD have physiological and psychological problems, cannot live normally and eventually die of complications such as infection [2]. It also causes a reduction in the patient's cognitive capacity. AD is the primary cause of senile dementia [2]. The WHO states that "Dementia is a term for several diseases that affect memory, thinking, and the ability to perform daily activities." Alzheimer's disease is the most common form of dementia and may contribute to 60–70% of cases [3]. According to the reports of the World Health Organization (WHO), "about 55 million people worldwide currently live with

dementia, and this number is expected to reach 139 million by the year 2050" [4]. According to a Lancet study (2021), Alzheimer's and other dementias claimed approximately 129,000 lives in India in 2019, marking the highest number of Alzheimer's-related deaths in the last three decades; between 1990 and 2019, Alzheimer's-related deaths in India increased nearly five times over, highlighting a significant rise in the disease's mortality rate in the country [5].

Existing treatments for Alzheimer's disease are "primarily palliative," aiming to delay and slow down cognitive decline and manage symptoms without providing an actual cure or addressing the root cause of the problem. In other words, these treatments make a difficult situation seem better and less serious but do not actually solve the problem [6,7]. Currently available pharmacological options, such as acetylcholinesterase inhibitors (donepezil, rivastigmine, and galantamine) and N-methyl-D-aspartate (NMDA) receptor antagonists (memantine), only provide symptomatic relief. They

do not prevent the progression of neurodegeneration and are associated with several adverse effects, including nausea, vomiting, dizziness, and hepatotoxicity, limiting their long-term use [8]. Owing to these limitations, there is a growing interest in natural products as potential alternative therapies for Alzheimer's disease. Among these, plant-derived polyphenols have emerged as promising candidates due to their neuroprotective, antioxidant, anti-inflammatory, and anti-amyloidogenic properties. Quercetin is a naturally occurring dietary flavonoid, a type of polyphenol, that is abundantly found in various fruits, vegetables, and beverages, such as "onions, apples, berries, capers, red wine, and green or black tea" [10]. Belonging to the subclass of flavonols, quercetin has recently attracted significant interest due to its strong antioxidant, anti-inflammatory, and neuroprotective properties [11]. These properties have made it a promising candidate for the prevention and treatment of Alzheimer's disease

(AD), which is characterized by progressive cognitive decline and memory loss.

II. Pathological Mechanism of Alzheimer's Disease

The key neuropathological features of AD include aggregation of β -Amyloid ($A\beta$) protein into neuritic plaques, the formation of hyperphosphorylated tau protein neurofibrillary tangles (NFTs) and considerable neuronal loss [12,13]. Research studies indicates that $A\beta$ and NFT can cause induction of chronic and persistent neuroinflammation in AD patients. This inflammation is marked by the activation of macrophages in the brain, and the excessive release of pro-inflammatory cytokines and chemokines such as interleukin-1 β (IL-1 β), interleukin-6 (IL-6) and tumor necrosis factor (TNF) [14]. In turn, this prolonged neuroinflammation can induce further production of $A\beta$ and NFT, exacerbating neurotoxicity and triggering neuronal apoptosis [15].




Fig 1: Alzheimer's Disease Pathogenesis [52]

2.1 Cholinergic Hypothesis

Acetylcholine (ACh), a key cholinergic neurotransmitter, plays a crucial role in various brain functions, including memory, attention, learning, and other cognitive processes [16]. In Alzheimer's disease (AD), a decline in ACh-mediated neurotransmission in the cerebral cortex and hippocampus is linked to worsening clinical symptoms [17]. The degeneration of cholinergic

neurons in the basal forebrain occurs due to reduced activity of acetylcholine transferase (ChAT), the enzyme responsible for ACh synthesis. Simultaneously, the activity of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) increases, likely due to β -amyloid ($A\beta$) deposition, which disrupts choline uptake and ACh release [18,19]. This imbalance, characterized by decreased ChAT activity and elevated AChE and BChE levels,

results in a significant reduction of ACh in AD patients. As the disease progresses, neurotransmitter

depletion and impaired signal transmission contribute to cognitive decline and memory loss [20].




Fig 2: Cholinergic Hypothesis of Alzheimer's Disease [26]

2.2 Amyloid Hypothesis

Amyloid precursor protein (APP) is a transmembrane protein abundantly found in the brain, primarily localized at neuronal synapses. It plays a crucial role in neurite growth, synaptogenesis, transmembrane signaling, and cell adhesion [18]. The neurotoxic protein β -amyloid ($A\beta$) is generated when APP undergoes cleavage by β -secretase and γ -secretase [21]. $A\beta$ exists in multiple forms, including monomers, oligomers, polymers, and insoluble fibrous aggregates. Over time, soluble $A\beta$ monomers interact and progressively form oligomers, polymers, and fibrous aggregates,

eventually leading to the formation of $A\beta$ plaques [22]. These plaques initially accumulate in the cerebral cortex and later spread to other brain regions, such as the hippocampus and basal forebrain, as the disease progresses. This characteristic feature is commonly observed in the brains of Alzheimer's disease (AD) patients. The buildup of $A\beta$ triggers neuroinflammation and initiates a neurodegenerative cascade, contributing to the formation of neurofibrillary tangles (NFTs) and ultimately resulting in neuronal loss in the affected brain regions [23].




Fig 3: Amyloid Hypothesis of Alzheimer's Disease [27]

2.3 Tau Protein Hypothesis

Tau is a soluble microtubule-associated protein (MAP) that plays a crucial role in stabilizing microtubules. Its phosphorylation occurs at various sites, including the N-terminal region (e.g., Ser46, Thr123, Ser198), the repeat region (Ser262, Ser356), and the C-terminal region (e.g., Ser396, Ser400, Thr403), and is regulated by several enzymes such as A kinase, C kinase, cyclin-dependent kinase 5 (CDK-5), glycogen synthase kinase 3 β (GSK-3 β), and mitogen-activated protein kinase (MAPK) [24]. In a healthy brain, tau phosphorylation levels are low, whereas in Alzheimer's disease (AD), tau undergoes hyperphosphorylation, a process primarily driven by

β -amyloid (A β) accumulation and neuroinflammation [17]. A β promotes tau hyperphosphorylation by increasing the activity of GSK-3 β and CDK-5 [24]. Hyperphosphorylated tau aggregates into paired helical filaments (PHFs), which subsequently form neurofibrillary tangles (NFTs). These pathological tau aggregates contribute to neuronal apoptosis through the activation of receptor-interacting protein kinase 1 (RIPK1), receptor-interacting protein kinase 3 (RIPK3), and mixed lineage kinase domain-like pseudokinase (MLKL), as well as necroptosis and inflammation mediated by the nuclear factor kappa-B (NF- κ B) pathway [25].




Fig 4: Tau Protein Hypothesis of Alzheimer's Disease [28]

2.4 Oxidative Stress Hypothesis

The oxidative stress hypothesis suggests that oxidative stress reactions and the excessive generation of reactive oxygen species (ROS) play a significant role in Alzheimer's disease (AD) pathology [29]. Under AD conditions, there is an imbalance in active metal ions, particularly copper (Cu), zinc (Zn), and iron (Fe). When these metal ions interact with amyloid-beta (A β), they can act as catalysts for ROS production. Additionally, in the cortex and hippocampus of AD patients, the catalytic function of iron in cytochrome c (hydroxide reductase), a key component of the mitochondrial energy transduction system, is impaired. This leads to increased release of superoxide anions and a decline in antioxidant

enzyme activity, including catalase and glutathione peroxidase. Mitochondrial dysfunction further contributes to ROS generation by causing electron leakage in the respiratory chain, which then interacts with superoxide anions, exacerbating oxidative damage [30]. The excessive accumulation of ROS disrupts neuronal biochemical pathways, impairs neural plasticity, and accelerates the aging process [31]. Since mitochondria are the primary source of ROS in cells, an overload of ROS leads to mitochondrial dysfunction and loss of homeostasis [32]. Moreover, in the early stages of AD, ROS has been implicated in promoting A β aggregation and tau hyperphosphorylation, further contributing to disease progression [22]. Additionally, oxidative stress triggers a cascade of inflammatory responses

by activating microglia and astrocytes, the immune cells of the central nervous system (CNS). These activated cells release pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF- α), interleukin-1 beta (IL-1 β), and interleukin-6 (IL-6),

further amplifying oxidative damage and worsening neuronal injury. This persistent neuroinflammatory state contributes to the progression of AD pathology, promoting sustained neuronal damage and cognitive deterioration.




Fig 5: Oxidative Stress Hypothesis of Alzheimer's Disease ^[36]

2.5 Neuroinflammatory Hypothesis

Growing research evidence indicates that the progression of Alzheimer's disease (AD) is strongly linked to neuroinflammation ^[33]. In the early stages of AD, amyloid-beta (A β) triggers the activation of microglia by upregulating the expression of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF- α), interleukin-1 beta (IL-1 β), and interleukin-6 (IL-6). This creates a neuroinflammatory environment, which subsequently leads to astrocyte activation and neuronal damage ^[34]. Neuronal injury acts as damage-associated molecular patterns (DAMPs), further sustaining the activation of microglia and astrocytes, resulting in chronic neuroinflammation. This persistent inflammatory state contributes to progressive neuronal apoptosis, exacerbates brain damage, and ultimately gives rise to key pathological features of AD. While A β plaques and

neurofibrillary tangles (NFTs) are considered the primary hallmarks of AD, ongoing inflammatory responses have also been widely observed in the brains of most AD patients ^[35]. This sustained neuroinflammatory cascade not only worsens A β deposition and tau hyperphosphorylation but also hinders the brain's ability to clear misfolded proteins, perpetuating the pathological cycle of AD. While A β plaques and neurofibrillary tangles (NFTs) are widely recognized as the primary hallmarks of AD, increasing evidence suggests that chronic inflammation is equally critical in driving neuronal dysfunction and cognitive decline. Given the growing understanding of neuroinflammation's role in AD, developing therapeutic interventions that target microglial activation, cytokine release, and inflammasome regulation could be a promising strategy for slowing or halting disease progression.




Fig 6: Neuroinflammatory Hypothesis of Alzheimer's Disease [37]

III. Mechanisms of Quercetin in Alzheimer's Disease

Quercetin, a prominent dietary flavonoid, exhibits a wide range of pharmacological actions that collectively contribute to its neuroprotective potential in Alzheimer's disease (AD). It targets several pathological mechanisms associated with the disease, making it a multipotent therapeutic candidate.

3.1. Antioxidant Activity

One of the most recognized mechanisms of quercetin is its antioxidant potential. It functions as a scavenger of reactive oxygen species (ROS), thereby reducing oxidative stress in neuronal tissues. Quercetin is known to scavenge reactive oxygen species (ROS), chelate metal ions, and enhance endogenous antioxidant defenses such as glutathione (GSH) and superoxide dismutase (SOD) [11]. Oxidative damage is a major contributor to AD progression, and by modulating oxidative balance, quercetin protects neurons from mitochondrial dysfunction and cell death [38]. Furthermore, quercetin may inhibit lipid peroxidation and DNA oxidation, thereby preserving cellular integrity.

3.2. Anti-inflammatory Effects

Quercetin is also well known for its anti-inflammatory properties. Neuroinflammation, primarily mediated by microglial cells and astrocytes, plays a critical role in the progression of

AD. Quercetin suppresses microglial activation and downregulates pro-inflammatory cytokines such as $\text{TNF-}\alpha$, $\text{IL-1}\beta$, and IL-6 [39]. This downregulation occurs through the inhibition of signaling pathways like $\text{NF-}\kappa\text{B}$ and MAPK, which are key regulators of inflammatory responses. As a result, quercetin contributes to the reduction of chronic inflammation and neuronal damage.

3.3. Inhibition of Aβ Aggregation

Amyloid- β ($\text{A}\beta$) aggregation into insoluble fibrils is a hallmark pathological feature of Alzheimer's disease. Quercetin has been shown to inhibit $\text{A}\beta$ fibril formation and destabilize existing aggregates [40]. It interacts with $\text{A}\beta$ peptides and interferes with the self-assembly process, thereby reducing plaque burden in brain tissues. In animal models, quercetin treatment reduced $\text{A}\beta$ deposition and improved memory and cognition, indicating its potential as an anti-amyloidogenic agent.

3.4. Tau Dephosphorylation and Inhibition of Tau Pathology

Another important target in AD pathology is tau protein hyperphosphorylation, which leads to neurofibrillary tangle formation. Studies have demonstrated that quercetin reduces tau hyperphosphorylation by inhibiting kinases such as $\text{GSK-3}\beta$ [41]. By modulating tau phosphorylation status, quercetin contributes to the preservation of microtubule stability and prevents neuronal cytoskeletal collapse. This tau-targeting mechanism

is especially significant given the correlation between tau pathology and disease severity.

3.5. Neurogenesis Stimulation

In addition to its protective functions, quercetin also plays a role in promoting neuronal regeneration. In animal models, quercetin promotes neurogenesis in the hippocampus, which is critical for memory formation and cognitive function [42]. The hippocampus is one of the primary brain regions affected in Alzheimer's disease, and the ability to stimulate new neuronal growth holds promise for cognitive recovery. This effect is likely mediated through pathways involving brain-derived neurotrophic factor (BDNF) and other growth factors.

3.5. Modulation of Autophagy

Recent studies suggest that quercetin can also influence autophagy—the cellular process responsible for the clearance of misfolded proteins and damaged organelles. By enhancing autophagic flux, quercetin facilitates the degradation of accumulated toxic proteins such as A β and hyperphosphorylated tau, contributing to overall neuroprotection.

3.6. Blood-Brain Barrier Penetration and Pharmacokinetics

Quercetin has demonstrated the ability to cross the blood-brain barrier (BBB), an essential property for central nervous system drugs. However, its poor water solubility and rapid metabolism limit its bioavailability. These limitations have prompted the development of nanoformulations and targeted delivery systems to enhance its CNS penetration and therapeutic potential.




Fig 7: Mechanism of Action and Delivery Systems of Quercetin in Alzheimer's Disease^[51]

IV. Preclinical Studies on Quercetin in Alzheimer's Disease

The therapeutic potential of quercetin in Alzheimer's disease (AD) has been explored through a wide range of in vitro and in vivo studies. These preclinical experiments provide essential insights into how quercetin interacts with the molecular and cellular hallmarks of AD, offering a foundation for future clinical trials.

4.1. In-vitro Studies

In vitro studies have consistently demonstrated the protective role of quercetin in neuronal cells exposed to AD-related stressors. "Ishige et al. (2001) found that quercetin

significantly attenuated hydrogen peroxide (H₂O₂)-induced oxidative damage in PC12 neuronal cells," suggesting its strong antioxidative function at the cellular level^[38]. The flavonoid acted by directly neutralizing free radicals and boosting the expression of intrinsic antioxidant enzymes such as catalase and superoxide dismutase. Another noteworthy in vitro study investigated the impact of quercetin on amyloid-beta toxicity. "Ansari et al. (2009) reported that quercetin treatment prevented A β 1–42-induced cell death in cultured cortical neurons by modulating oxidative stress and mitochondrial function." These experiments also showed that quercetin could restore mitochondrial membrane potential and reduce ROS

accumulation^[41]. Moreover, quercetin has demonstrated anti-inflammatory effects in microglial cell cultures. It inhibits the release of pro-inflammatory mediators like nitric oxide (NO), TNF- α , and IL-6, primarily through "the suppression of the NF- κ B signaling pathway"^[39]. These findings support its application as an anti-inflammatory and anti-amyloidogenic agent in early AD intervention strategies.

4.2. In-vivo Studies

Numerous animal studies have reinforced the beneficial role of quercetin in models of Alzheimer's disease. These studies range from behavioral analyses to biochemical evaluations, revealing its potential to mitigate cognitive decline and pathological progression. "Rishitha et al. (2021) evaluated the effects of oral quercetin in A β 1-42-induced Alzheimer's rats and reported improved learning, memory retention, and locomotor activity compared to untreated controls." The study also showed a marked reduction in lipid peroxidation levels, accompanied by enhanced activity of endogenous antioxidants like glutathione (GSH) and catalase^[42]. Histopathological observations indicated decreased neuronal degeneration in the hippocampus and cortex, highlighting the compound's neuroprotective capability. Another significant in vivo study was conducted by Sabogal-Guáqueta et al. (2015) using 3xTg-AD mice, a transgenic mouse model that mimics both amyloid and tau pathologies of human AD^[40]. "When treated with quercetin over a six-month period, these mice showed substantial improvements in cognitive function, as assessed by the Morris Water Maze test." Furthermore, biochemical assays revealed that quercetin significantly reduced levels of soluble A β peptides and hyperphosphorylated tau protein in the hippocampus. Importantly, this study also demonstrated a reduction in inflammatory markers and glial activation, suggesting that quercetin not only halts but may also reverse ongoing neurodegeneration. The long-term administration of quercetin was well tolerated by the mice and did not induce any observable toxicity, further supporting its potential as a safe neurotherapeutic compound.

More recently, functionalized quercetin nanoparticles have been evaluated to overcome bioavailability challenges. In a study by Sun et al. (2020), PLGA-encapsulated quercetin nanoparticles (PLGA@QT) were administered to APP/PS1 mice, a model of familial Alzheimer's disease^[43]. The formulation not only reversed cognitive deficits but also inhibited and disaggregated A β 42 fibrils, suggesting a superior efficacy over free quercetin. This study also confirmed the safety of PLGA@QT through cytotoxicity assays in SH-

SY5Y cells and toxicity evaluations in vivo. In another innovative experiment, Ghosh et al. (2013) used PLGA nanoencapsulated quercetin to treat ischemia-reperfusion-induced neurodegeneration in rats. This model is often used to simulate acute oxidative stress and neuroinflammation akin to those in Alzheimer's pathology. The treatment resulted in increased neuronal survival in the hippocampus, downregulation of iNOS and caspase-3, and significant behavioral recovery^[44]. Together, these in vivo studies not only validate quercetin's multifunctional role in addressing AD pathology—including oxidative stress, inflammation, A β aggregation, and tau hyperphosphorylation—but also suggest that nanotechnology-assisted delivery may enhance its therapeutic potential.

V. Delivery Challenges of Quercetin

Although quercetin has shown significant potential in combating Alzheimer's disease due to its antioxidant, anti-inflammatory, and anti-amyloid properties, its therapeutic application is limited by several pharmacokinetic and delivery-related obstacles. These challenges are detailed below:

5.1. Poor Water Solubility

Quercetin is a hydrophobic compound with very low solubility in water, approximately 2.15 μ g/mL. This makes it difficult for the compound to dissolve in gastrointestinal fluids, which is a necessary step for oral absorption. This limited solubility results in poor oral bioavailability, which is a critical barrier for its use in chronic diseases like AD that require sustained and efficient delivery to the brain^[45]. Thus, even if administered in larger doses, its absorption efficiency remains extremely low.

5.2. Low Oral Bioavailability

Due to its poor solubility and extensive metabolism, quercetin exhibits low systemic bioavailability. When taken orally, only a small fraction reaches the bloodstream. It is subject to extensive phase II metabolism in the liver and intestines, where it is rapidly conjugated into glucuronides, sulfates, and methylated metabolites^[46]. This results in insufficient active quercetin levels reaching target tissues like the brain, reducing therapeutic impact.

5.3. Rapid Metabolism and Elimination

After absorption, quercetin is rapidly broken down into various metabolites by the liver and intestines. These metabolites often have reduced antioxidant and neuroprotective activity. The fast clearance from the body prevents sustained therapeutic levels, making it difficult to maintain a continuous neuroprotective effect in AD patients.

5.4. Limited Blood-Brain Barrier (BBB) Permeability

Despite its lipophilic nature, quercetin has limited ability to cross the BBB, which is a major obstacle in treating central nervous system disorders like Alzheimer's. Despite its lipophilic nature, quercetin exhibits low translocation across the BBB, which severely limits its effectiveness in targeting neuronal tissues in Alzheimer's disease^[39]. Thus, even if quercetin reaches the bloodstream, it may not effectively accumulate in the brain.

5.5. Efflux by P-glycoprotein Transporters

The endothelial cells of the BBB express efflux transporters such as P-glycoprotein (P-gp), which actively pump out xenobiotics, including flavonoids like quercetin. As a result, even when quercetin reaches the brain endothelium, P-gp transporters limit its accumulation in brain tissue by pumping it back into the systemic circulation.

5.6. Instability in Biological Systems

Quercetin is sensitive to oxidative degradation and tends to be unstable in physiological environments, especially under alkaline pH, heat, and light. This chemical instability complicates storage and formulation, and reduces the effectiveness of quercetin-based therapies over time, especially in standard supplement form.

5.7. Dose Escalation and Toxicity Risks

Because of low absorption and high clearance, higher doses of quercetin are often required to achieve therapeutic effects. However, these high doses may result in side effects such as gastrointestinal irritation, pro-oxidant effects, and hepatotoxicity. This creates difficulty in determining a safe yet effective dose range, especially for chronic diseases like Alzheimer's that require long-term management.

These factors result in low bioavailability and reduced therapeutic effectiveness. Therefore, advanced drug delivery systems are being explored to overcome these challenges.

VI. Nanotechnology Based Drug Delivery Systems

The use of nanotechnology-based drug delivery systems has emerged as a transformative strategy to overcome the limitations associated with conventional quercetin delivery. Nanocarriers are engineered to improve the solubility, bioavailability, stability, and brain-targeting efficiency of therapeutic molecules, particularly those like quercetin with low oral bioavailability and limited BBB permeability. Some of the most promising nanotechnological systems explored for quercetin in Alzheimer's therapy include polymeric nanoparticles, solid lipid nanoparticles (SLNs), liposomes, and magnetic nanoparticles.

6.1. Polymeric Nanoparticles

Polymeric nanoparticles, especially those made from biodegradable polymers like poly(lactic-co-glycolic acid) (PLGA), have gained significant attention due to their safety profile, ability to protect quercetin from premature degradation, and controlled-release characteristics. In a study by Sun et al. (2021), PLGA-functionalized quercetin nanoparticles (PLGA@QT) were developed and tested in vitro and in vivo. These nanoparticles exhibited high stability and biocompatibility and were effective in targeting Alzheimer's pathology^[47]. PLGA@QT inhibited and disassembled A β 42 fibrils and reversed cognitive and memory impairments in APP/PS1 mice, demonstrating both anti-amyloidogenic and neurorestorative effects. Moreover, a dose-dependent improvement in spatial memory was observed, suggesting enhanced therapeutic efficacy over free quercetin formulations.

6.2. Solid Lipid Nanoparticles (SLNs)

SLNs are composed of biocompatible lipids that remain solid at room and body temperature, providing a stable matrix for the encapsulation of hydrophobic drugs like quercetin. These carriers offer the advantage of protecting the loaded drug from chemical degradation and controlling its release, making them suitable for brain delivery. Several studies have demonstrated that SLN-based quercetin formulations exhibit higher permeability across biological barriers, reduced toxicity, and prolonged circulation time in plasma. These attributes make SLNs an attractive option for sustained delivery in chronic conditions like Alzheimer's disease.

6.3. Liposomes

Liposomes are spherical vesicles composed of phospholipid bilayers that can encapsulate both hydrophilic and lipophilic compounds. They are known for their biocompatibility, flexibility, and ability to mimic natural cell membranes. Priprem et al. (2008) investigated intranasally administered quercetin liposomes in male Wistar rats. The results were promising: The elevated plus maze test showed anxiolytic-enhancing effects of quercetin liposomes, while the Morris water maze test revealed cognitive function improvement in rats compared with free quercetin treatment animals^[48]. This study confirmed that intranasal delivery allowed the liposomes to bypass the blood-brain barrier, delivering quercetin directly to the brain with lower doses and reduced systemic toxicity.

6.4. Nano-carriers

The initial investigation into the therapeutic and protective potential of quercetin nanoparticles (QNPs) in an animal model of Alzheimer's disease was conducted by Rifaai and colleagues [50]. In this study, AD-like pathology was induced in rats by administering aluminum chloride (AlCl_3) orally. The neurotoxic effects of AlCl_3 caused degenerative changes in the hippocampus, but these effects were significantly reduced when QNPs were given simultaneously as a preventive intervention. "The formation of amyloid plaques and neurofibrillary tangles induced by AlCl_3 was nearly eliminated" in rats treated with QNPs, indicating a strong protective influence. Moreover, QNPs preserved cell proliferation in the dentate gyrus region of the hippocampus. The researchers concluded that delivering quercetin in nanoparticle form improved its bioavailability and minimized neuronal damage caused by AlCl_3 at multiple biological levels, including molecular, cellular, and subcellular layers.

6.5. Magnetic Nanoparticles (SPIONs)

Superparamagnetic iron oxide nanoparticles (SPIONs) have emerged as multifunctional carriers capable of targeted drug delivery, MRI imaging, and responsive release. These nanoparticles can be guided to specific sites, such as the brain, using external magnetic fields. A notable study in this field is by Jajin et al. (2023). To enhance the solubility and bioavailability of quercetin, Jajin et al. employed magnetic targeting using superparamagnetic nanoparticles [104]. They engineered quercetin-linked superparamagnetic iron oxide nanoparticles (QT-SPIONs) and assessed their impact on AlCl_3 -induced Alzheimer's-like symptoms in rats. The results showed that the QT-SPION conjugates were considerably more effective than free quercetin in improving bioavailability and brain penetration. In fact, quercetin, when delivered in this conjugated form, showed an improved ability to cross into brain tissue. Additionally, the QT-SPION treatment increased the expression of antioxidant enzymes such as SOD1, CAT, and GPX1, while iNOS levels were reduced. There was also an upregulation of the anti-apoptotic gene BCL2 and a downregulation of the pro-apoptotic gene BAX. In rat models where memory deficits were caused by aluminum exposure, "QT-SPION treatment reversed memory impairment and mitigated symptoms resembling AD." The study further revealed "a significant decrease in amyloid precursor protein (APP) gene expression" in the QT-SPION-treated group, indicating the potential of these nanoparticles in slowing or preventing AD development. Overall, the findings support that quercetin-conjugated nanoparticles, due to their

capacity to cross the blood-brain barrier (BBB), "could serve as an effective delivery system for long-term neuroprotection and the management of Alzheimer's disease."

6.6. Dendrimers and other Advanced Systems

Emerging nanocarriers such as dendrimers and nanomicelles (nanoemulsions) are also being explored for quercetin delivery. These systems offer high surface functionality, allowing for targeted delivery and improved drug loading. Although research is still in its early stages, these carriers present great potential for future clinical translation. Their nanoscale size and modifiable surfaces make them suitable for crossing the BBB and targeting affected neurons with precision.

VII. CONCLUSION

Quercetin holds great promise as a neuroprotective agent in the treatment of Alzheimer's Disease (AD) due to its wide-ranging biological activities. As a naturally occurring flavonoid, quercetin exerts potent antioxidant, anti-inflammatory, and anti-amyloid effects, which are critical in combating the multifactorial pathology of AD. Its ability to modulate multiple pathological features of AD, such as oxidative stress, neuroinflammation, $\text{A}\beta$ aggregation, and tau phosphorylation, makes it a compelling candidate for therapeutic development. These multi-target actions suggest that quercetin may not only slow disease progression but also provide symptomatic relief by preserving neuronal integrity and enhancing cognitive performance. However, despite its significant potential, quercetin's clinical translation has been hindered primarily by its poor water solubility, rapid metabolism, and low oral bioavailability. To overcome these limitations, recent advancements in nanotechnology—such as PLGA nanoparticles, liposomes, and other polymeric delivery systems—have been extensively studied. These systems have shown promise in improving quercetin's pharmacokinetic profile, protecting it from degradation, and enhancing its ability to cross the blood-brain barrier (BBB). Moreover, formulations like intranasal quercetin delivery and functionalization with targeting ligands (e.g., Tet-1 peptide) have further improved its brain-targeting efficiency. Continued preclinical and clinical investigations are warranted to validate its safety, efficacy, and long-term benefits in AD patients. Future research should also explore optimal dosing strategies, combination therapies with other natural compounds, and the long-term effects of chronic administration in human subjects. Overall, quercetin represents a powerful natural therapeutic candidate, and with further innovation in

drug delivery technologies and clinical trials, it may become an effective component of the multifaceted approach needed to manage and treat Alzheimer's disease.

VIII. FUTURE PROSPECTIVES

The limitations associated with poor solubility, instability, low bioavailability, and limited brain permeability of quercetin demand next-generation solutions. Nanotechnology has offered a leap forward, and now, research is shifting to smart, targeted, and personalized nanocarrier systems. The future of quercetin-based therapy in Alzheimer's is promising with the advancement of nanotechnology. Innovations like hybrid nanoparticles, exosomes, ligand-functionalized carriers, and gene-editing platforms open up exciting and transformative possibilities for overcoming traditional therapeutic limitations. Multimodal, responsive, and personalized delivery systems are likely to dominate next-generation strategies, offering hope for a more effective, targeted, and sustained intervention in Alzheimer's disease. The following emerging technologies highlight promising future directions.

8.1. Hybrid Nanoparticles

Hybrid nanoparticles are engineered by combining multiple materials (e.g., polymers and lipids) to gain the benefits of both. For example, lipid-polymer hybrid nanoparticles (LPNs) have a polymeric core (like PLGA) that provides structural integrity and controlled release, and a lipid shell for enhanced biocompatibility and membrane fusion potential.

These systems offer:

- Better encapsulation efficiency of polyphenols
- Enhanced circulation time in the bloodstream
- Greater BBB permeability
- Potential for surface functionalization for targeted delivery

Such hybrid platforms can be engineered to load both hydrophilic and hydrophobic molecules and allow for sustained, stimuli-responsive drug release^[53]. In Alzheimer's models, hybrid nanoparticles may be optimized for dual delivery of quercetin to act synergistically at the site of neuroinflammation.

8.2. Exosome-Based Delivery Systems

Exosomes are naturally occurring extracellular vesicles secreted by almost all cell types. They play a crucial role in intercellular communication and have innate capabilities to cross the BBB, making them a biocompatible and non-immunogenic vehicle for delivering therapeutic agents.

Exosome-based delivery for polyphenols offers:

- Enhanced BBB penetration through receptor-mediated endocytosis
- Protection of the polyphenol from degradation
- Reduced toxicity and immune response
- Ability to target neuronal or glial cells

Loading quercetin into autologous exosomes derived from patient stem cells could offer a personalized medicine approach for Alzheimer's treatment^[54].

8.3. Ligand-Targeted Nanocarriers

The concept of ligand-based targeting involves modifying the nanoparticle surface with ligands that bind to specific receptors on BBB or neuronal cells, enhancing site-specific drug delivery.

Popular ligands for AD-focused polyphenol nanodelivery include:

- Transferrin – binds to transferrin receptors at the BBB
- Lactoferrin
- Apolipoprotein E (ApoE)
- Tet-1 peptide – binds neuronal gangliosides
- RGD peptide – targets integrins on activated endothelial cells

Developing ligand-conjugated nanoparticles carrying both diagnostic markers (e.g., contrast agents) and therapeutics (e.g., quercetin) could facilitate theranostic applications in Alzheimer's diagnosis and treatment^[55].

8.4. Gene-Polyphenol Combination Therapy

Alzheimer's disease has a strong genetic component, and recent studies explore combining gene therapy with polyphenol delivery for a synergistic therapeutic approach.

For instance:

- Polyphenols like resveratrol activate SIRT1 gene pathways associated with neuroprotection
- Combining polyphenol-loaded nanoparticles with small interfering RNA (siRNA) targeting genes like BACE1 (which promotes amyloid beta production) can enhance therapeutic outcomes.

Future nanocarriers may deliver both quercetin and a gene-modifying payload (e.g., siRNA or antisense oligonucleotides) directly to brain regions affected by AD^[56].

8.5. CRISPR with Nano-Polyphenols

The revolutionary CRISPR/Cas9 genome-editing system offers the potential to permanently correct genetic mutations associated with Alzheimer's. However, delivering CRISPR safely into the brain remains a challenge.

Quercetin-based nanocarriers can potentially:

- Serve as dual-function systems carrying both gene-editing tools and antioxidants
 - Reduce the neuroinflammation caused by CRISPR-induced immune activation
 - Protect CRISPR-Cas9 payloads from degradation during systemic circulation
- Encapsulating CRISPR-Cas9 plasmids in biocompatible nanoparticles with polyphenolic components like quercetin may enhance intracellular uptake, reduce toxicity, and enable targeted gene editing in neurons^[57]. Designing quercetin-CRISPR co-delivery systems can allow for simultaneous gene editing and neuroprotection, offering a futuristic and disease-modifying approach to Alzheimer's.

REFERENCES

- [1]. Zivari-Ghader, T., Valioglu, F., Eftekhari, A., Aliyeva, I., Beylerli, O., Davran, S., Cho, W. C., Beilerli, A., Khalilov, R., & Javadov, S. (2024). Recent progresses in natural based therapeutic materials for Alzheimer's disease. *Heliyon*, 10(4), e26351. <https://doi.org/10.1016/j.heliyon.2024.e26351>
- [2]. Rayees Ahmad Naik, Roshni Rajpoot, Raj Kumar Koiri, Rima Bhardwaj, Abdullah F. Aldairi, Ayman K. Johargy, Hani Faidah, Ahmad O. Babalghith, Ahmed Hjjazi, Walaa F. Alsanie, Abdulhakeem S. Alamri, Majid Alhomrani, Abdulaziz Alsharif, Anastasiia Shkodina, Sandeep Kumar Singh, Dietary supplementation and the role of phytochemicals against the Alzheimer's disease: Focus on polyphenolic compounds, *The Journal of Prevention of Alzheimer's Disease*, Volume 12, Issue 1, 2025, 100004, ISSN 2274-5807, <https://doi.org/10.1016/j.tjpad.2024.100004>
- [3]. Gauthier S, Webster C, Servaes S, Morais JA, Rosa-Neto P. World Alzheimer Report 2022: Life after diagnosis: Navigating treatment, care and support [Internet]. London; 2022 Sep. <https://www.alzint.org/resource/world-alzheimer-report-2022/>
- [4]. Shin JH. Dementia Epidemiology Fact Sheet 2022. *Ann Rehabil Med* [Internet]. 2022;46(2):53–9, <https://doi.org/10.31887/DCNS.2009.11.2/hb rodaty>
- [5]. Ravindranath, V., & Sundarakumar, J. S. (2021). Changing demography and the challenge of dementia in India. *Nature reviews. Neurology*, 17(12), 747–758.
- [6]. Poddar MK, Chakraborty A, Banerjee S, Poddar MK, Chakraborty A, Banerjee S. Neurodegeneration: Diagnosis, Prevention, and Therapy. *Oxidoreductase* [Internet]. 2021. Jan 27; Available from: <https://www.intechopen.com/chapters/74857>
- [7]. Lamprey RNL, Chaulagain B, Trivedi R, Gothwal A, Layek B, Singh J. A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics. *Int J Mol Sci* [Internet]. 2022. Feb 1. 23(3):1851. Available from: [/pmc/articles/PMC8837071/](https://pmc/articles/PMC8837071/)
- [8]. Grossberg GT. Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease: Getting On and Staying On. *Curr Ther Res Clin Exp* [Internet]. 2003. Apr 1;64(4):216–35. Available from: [/pmc/articles/PMC4052996/](https://pmc/articles/PMC4052996/)
- [9]. Deng, M., Yan, W., Gu, Z., Li, Y., Chen, L., & He, B. (2023). Anti-Neuroinflammatory Potential of Natural Products in the Treatment of Alzheimer's Disease. *Molecules* (Basel, Switzerland), 28(3), 1486. <https://doi.org/10.3390/molecules28031486>
- [10]. Li, Y., Yao, J., Han, C., Yang, J., Chaudhry, M. T., Wang, S., Liu, H., & Yin, Y. (2016). "Quercetin, Inflammation and Immunity." *Nutrients*, 8(3), 167. <https://doi.org/10.3390/nu8030167>
- [11]. Boots, A. W., Haenen, G. R. M. M., & Bast, A. (2008). "Health effects of quercetin: From antioxidant to nutraceutical." *European Journal of Pharmacology*, 585(2–3), 325–337. <https://doi.org/10.1016/j.ejphar.2008.03.008>
- [12]. Dansokho C., Heneka M.T. Neuroinflammatory responses in Alzheimer's disease. *J. Neural Transm.* 2018;125:771–779. doi: 10.1007/s00702-017-1831-7
- [13]. Onyango I.G., Jauregui G.V., Carna M., Bennett J.P., Jr., Stokin G.B. Neuroinflammation in Alzheimer's Disease. *Biomedicines*. 2021;9:524. doi: 10.3390/biomedicines9050524
- [14]. Olajide O.A., Sarker S.D. Alzheimer's disease: Natural products as inhibitors of neuroinflammation. *Inflammopharmacology*. 2020;28:1439–1455. doi: 10.1007/s10787-020-00751-1
- [15]. Sung P.S., Lin P.Y., Liu C.H., Su H.C., Tsai K.J. Neuroinflammation and Neurogenesis in Alzheimer's Disease and Potential Therapeutic Approaches. *Int. J. Mol. Sci.* 2020;21:701. doi: 10.3390/ijms21030701.
- [16]. Nedogreeva O.A., Evtushenko N.A., Manolova A.O., Peregud D.I., Yakovlev A.A., Lazareva N.A., Gulyaeva N.V., Stepanichev M.Y. Oxidative Damage of Proteins Precedes Loss of Cholinergic Phenotype in the Septal Neurons of Olfactory

- Bulbectomized Mice. *Curr. Alzheimer Res.* 2021;18:1140–1151. doi: 10.2174/1567205019666211223094051
- [17]. Noori T., Dehpour A.R., Sureda A., Sobarzo-Sanchez E., Shiroomi S. Role of natural products for the treatment of Alzheimer's disease. *Eur. J. Pharmacol.* 2021;898:173974. doi: 10.1016/j.ejphar.2021.173974
- [18]. Patil P., Thakur A., Sharma A., Flora S.J.S. Natural products and their derivatives as multifunctional ligands against Alzheimer's disease. *Drug Dev. Res.* 2020;81:165–183. doi: 10.1002/ddr.21587
- [19]. Xia Y., Wu Q., Mak S., Liu E.Y.L., Zheng B.Z.Y., Dong T.T.X., Pi R., Tsim K.W.K. Regulation of acetylcholinesterase during the lipopolysaccharide-induced inflammatory responses in microglial cells. *FASEB J.* 2022;36:e22189. doi: 10.1096/fj.202101302RR
- [20]. Liang Z., Li X., Luo X., Luo H., Chen Y., Cai M., Zhong X., Fang Y., Guo T., Shi Y., et al. The Aptamer Ob2, a novel AChE inhibitor, restores cognitive deficits and alleviates amyloidogenesis in 5xFAD transgenic mice. *Mol. Ther. Nucleic Acids.* 2022;28:114–123. doi: 10.1016/j.omtn.2022.02.018
- [21]. Dobson C.M. The Amyloid Phenomenon and Its Links with Human Disease. *Cold Spring Harb. Perspect. Biol.* 2017;9:a023648. doi: 10.1101/cshperspect.a023648
- [22]. Zhang Z., Wang S., Tan H., Yang P., Li Y., Xu L., Duan B., Liu Y. Advances in polysaccharides of natural source of the anti-Alzheimer's disease effect and mechanism. *Carbohydr. Polym.* 2022;296:119961. doi: 10.1016/j.carbpol.2022.119961
- [23]. Zhang Y.W., Thompson R., Zhang H., Xu H. APP processing in Alzheimer's disease. *Mol. Brain.* 2011;4:3–15. doi: 10.1186/1756-6606-4-3
- [24]. Zhang H., Wei W., Zhao M., Ma L., Jiang X., Pei H., Cao Y., Li H. Interaction between Abeta and Tau in the Pathogenesis of Alzheimer's Disease. *Int. J. Biol. Sci.* 2021;17:2181–2192. doi: 10.7150/ijbs.57078
- [25]. Dong Y., Yu H., Li X., Bian K., Zheng Y., Dai M., Feng X., Y., He Y., Yu B., et al. Hyperphosphorylated tau mediates neuronal death by inducing necroptosis and inflammation in Alzheimer's disease. *J. Neuroinflammation.* 2022;19:205–222. doi: 10.1186/s12974-022-02567-y
- [26]. Dias, Catarina & Rauter, Amélia. (2015). Carbohydrates and glycomimetics in Alzheimer's disease therapeutics and diagnosis. *RSC Drug Discovery Series.* 2015. 180-208.
- [27]. Hunk F. Kung, The β -Amyloid Hypothesis in Alzheimer's Disease: Seeing Is Believing, *ACS Medicinal Chemistry Letters* 2012 3 (4), 265-267, DOI: 10.1021/ml300058m
- [28]. Hanafy, Amira & Schoch, Susanne & Lamprecht, Alf. (2020). CRISPR/CAS9 delivery potentials in alzheimer's disease management: A mini review. *Pharmaceutics.* 12. 801. 10.3390/pharmaceutics12090801.
- [29]. Praticò D. Oxidative stress hypothesis in Alzheimer's disease: A reappraisal. *Trends Pharmacol. Sci.* 2008;29:609–615. doi: 10.1016/j.tips.2008.09.001
- [30]. Cheignon C., Tomas M., Bonnefont-Rousselot D., Faller P., Hureau C., Collin F. Oxidative stress and the amyloid beta peptide in Alzheimer's disease. *Redox Biol.* 2018;14:450–464. doi: 10.1016/j.redox.2017.10.014
- [31]. da Rosa M.M., de Amorim L.C., Alves J.V.d.O., Aguiar I.F.d.S., Oliveira F.G.d.S., da Silva M.V., dos Santos M.T.C. The promising role of natural products in Alzheimer's disease. *Brain Disord.* 2022;7:100049. doi: 10.1016/j.dscb.2022.100049
- [32]. Llanos-González E., Henares-Chavarino Á.A., Pedrero-Prieto C.M., García-Carpintero S., Frontiñán-Rubio J., Sancho-Bielsa F.J., Alcaín F.J., Peinado J.R., Rabanal-Ruiz Y., Durán-Prado M. Interplay Between Mitochondrial Oxidative Disorders and Proteostasis in Alzheimer's Disease. *Front. Neurosci.* 2019;13:1444–1453. doi: 10.3389/fnins.2019.01444
- [33]. Liu F., Dong B., Yang X., Yang Y., Zhang J., Jin D.-Q., Ohizumi Y., Lee D., Xu J., Guo Y. NO inhibitors function as potential anti-neuroinflammatory agents for AD from the flowers of *Inula japonica*. *Bioorganic Chem.* 2018;77:168–175. doi: 10.1016/j.bioorg.2018.01.009
- [34]. Al-Ghraiybah N.F., Wang J., Alkhalifa A.E., Roberts A.B., Raj R., Yang E., Kaddoumi A. Glial Cell-Mediated Neuroinflammation in Alzheimer's Disease. *Int. J. Mol. Sci.* 2022;23:10572. doi: 10.3390/ijms231810572
- [35]. Huang S., Liu W., Li Y., Zhang K., Zheng X., Wu H., Tang G. Design, Synthesis, and Activity Study of Cinnamic Acid Derivatives as Potent Antineuroinflammatory Agents. *ACS Chem. Neurosci.* 2021;12:419–429. doi: 10.1021/acschemneuro.0c00578
- [36]. Misrani, A., Tabassum, S., & Yang, L. (2021). Mitochondrial Dysfunction and

- Oxidative Stress in Alzheimer's Disease. In Frontiers in Aging Neuroscience (Vol. 13). Frontiers Media SA. <https://doi.org/10.3389/fnagi.2021.617588>
- [37]. Wong-Guerra, M., Calfio, C., Maccioni, R. B., & Rojo, L. E. (2023). Revisiting the neuroinflammation hypothesis in Alzheimer's disease: a focus on the druggability of current targets. In Frontiers in Pharmacology (Vol. 14). Frontiers Media SA. <https://doi.org/10.3389/fphar.2023.1161850>
- [38]. Ishige, K., Schubert, D., & Sagara, Y. (2001). "Flavonoids protect neuronal cells from oxidative stress by three distinct mechanisms." Free Radical Biology and Medicine, 30(4), 433–446. [https://doi.org/10.1016/S0891-5849\(00\)00373-6](https://doi.org/10.1016/S0891-5849(00)00373-6)
- [39]. Dajas, F. (2012). "Life or death: Neuroprotective and anticancer effects of quercetin." Journal of Ethnopharmacology, 143(2), 383–396. <https://doi.org/10.1016/j.jep.2012.07.005>
- [40]. Sabogal-Guáqueta, A. M., Munoz-Manco, J. I., Ramírez-Pineda, J. R., Lamprea-Rodriguez, M., Osorio, E., & Cardona-Gómez, G. P. (2015). "The flavonoid quercetin ameliorates Alzheimer's disease pathology and protects cognitive and emotional function in APP/PS1 mice." Aging and Disease, 6(5), 419. <https://doi.org/10.14336/AD.2015.0330>
- [41]. Ansari, M. A., Abdul, H. M., Joshi, G., Opii, W. O., & Butterfield, D. A. (2009). "Protective effect of quercetin in primary neurons against A β (1–42): relevance to Alzheimer's disease." Journal of Nutritional Biochemistry, 20(4), 269–275. <https://doi.org/10.1016/j.jnutbio.2008.03.002>
- [42]. Rishitha, N., Nirmaladevi, R., & Janakiraman, V. (2021). "Neuroprotective effect of quercetin in Alzheimer's disease: an in silico and in vivo study." Biomedicine & Pharmacotherapy, 134, 111126. <https://doi.org/10.1016/j.biopha.2020.111126>
- [43]. Sun, Y., Liu, W., Zhao, Y., Wang, X., & Wu, Y. (2020). "PLGA-functionalized quercetin nanoparticles reverse cognitive decline and inhibit β -amyloid aggregation in Alzheimer's mice." International Journal of Nanomedicine, 15, 789–802. <https://doi.org/10.2147/IJN.S233964>
- [44]. Ghosh, D., Scheepens, A., Vaidyanathan, J. B., & Mitra, J. (2013). "Oral administration of quercetin nanoformulation attenuates oxidative stress and neuronal cell loss in rats subjected to global cerebral ischemia." Neurochemistry International, 62(6), 782–789. <https://doi.org/10.1016/j.neuint.2013.02.011>
- [45]. Nair, H. K., Rao, K. V., Aalinkeel, R., Mahajan, S., Chawda, R., & Schwartz, S. A. (2006). "Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes." Clinical and Diagnostic Laboratory Immunology, 11(1), 63–69. <https://doi.org/10.1128/CDLI.11.1.63-69.2004>
- [46]. Manach, C., Scalbert, A., Morand, C., Rémésy, C., & Jiménez, L. (2005). "Polyphenols: food sources and bioavailability." The American Journal of Clinical Nutrition, 79(5), 727–747. <https://doi.org/10.1093/ajcn/79.5.727>
- [47]. Sun, Y., Liu, Z., Wang, L., Sun, L., & Luo, W. (2021). "Neuroprotective effect of PLGA-functionalized quercetin nanoparticles in Alzheimer's disease: inhibition of amyloid fibril formation and reversal of cognitive deficits." International Journal of Nanomedicine, 16, 1893–1907. <https://doi.org/10.2147/IJN.S294154>
- [48]. Priprem, A., Watanatorn, J., Sutthiparinyanont, S., Phachonpai, W., & Muchimapura, S. (2008). "Anxiolytic and cognitive effects of quercetin liposomes in rats." Nanomedicine: Nanotechnology, Biology and Medicine, 4(1), 70–78. <https://doi.org/10.1016/j.nano.2007.10.002>
- [49]. Jain, M., Saxena, M., Singh, R., & Meena, R. (2023). "Therapeutic efficacy of quercetin-conjugated magnetic nanoparticles in aluminium chloride-induced Alzheimer's disease rat model." Life Sciences, 314, 121353. <https://doi.org/10.1016/j.lfs.2022.121353>
- [50]. Rifaai R.A., Mokhemer S.A., Saber E.A., El-Aleem S.A.A., El-Tahawy N.F.G. Neuroprotective effect of quercetin nanoparticles: A possible prophylactic and therapeutic role in alzheimer's disease. J. Chem. Neuroanat. 2020;107:101795. doi: 10.1016/j.jchemneu.2020.101795.
- [51]. Kaur, K., Kulkarni, Y. A., & Wairkar, S. (2024). Exploring the potential of quercetin in Alzheimer's Disease: Pharmacodynamics, Pharmacokinetics, and Nanodelivery systems. In Brain Research (Vol. 1834, p. 148905). Elsevier BV. <https://doi.org/10.1016/j.brainres.2024.148905>
- [52]. Faiyaz, M., Ganayee, Mohd. A., Akhtar, S., Krishnan, S., Flora, B., Dogra, D., Jha, N. K.,

- Chellappan, D. K., Negi, P., Dua, K., Kesari, K. K., & Gupta, P. K. (2021). Nanomaterials in Alzheimer's disease treatment: a comprehensive review. In *Frontiers in Bioscience-Landmark* (Vol. 26, Issue 10). IMR Press. <https://doi.org/10.52586/4992>
- [53]. 131. Ha, D., Yang, N., & Nadithe, V. (2016). Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: Current perspectives and future challenges. *Acta Pharmaceutica Sinica B*, 6(4), 287–296. <https://doi.org/10.1016/j.apsb.2016.02.001>
- [54]. Yadav, H. K. S., Almokdad, A. A., Shrestha, N., & MohdSetapar, S. H. (2020). Hybrid nanoparticle systems for delivery of polyphenols: A promising approach against Alzheimer's disease. *Journal of Drug Delivery Science and Technology*, 60, 101946. <https://doi.org/10.1016/j.jddst.2020.101946>
- [55]. 133. Mathew, A., Fukuda, T., Nagaoka, Y., Hasumura, T., Morimoto, H., Yoshida, Y. & Maekawa, T. (2012). Curcumin-loaded PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer's disease. *PLOS ONE*, 7(3), e32616. <https://doi.org/10.1371/journal.pone.0032616>
- [56]. Li, Y., Li, L., Wu, J., Zhu, X., & Sun, H. (2021). RNA interference in Alzheimer's disease therapy: current approaches and future directions. *Drug Discovery Today*, 26(6), 1419–1431. <https://doi.org/10.1016/j.drudis.2021.01.024>
- [57]. Zhang, W., Zhang, Y., & He, Y. (2022). Delivery of CRISPR/Cas9 genome editing machinery for treating neurological disorders. *Journal of Controlled Release*, 341, 56–75. <https://doi.org/10.1016/j.jconrel.2021.12.007>